Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NDORMS researchers identify a subset of immune cells that could be a new therapeutic target to treat inflamed blood vessels in Giant Cell Arteritis (GCA) and other forms of inflammatory vascular disease.

Blood cells

The research, led by Prof Irina Udalova (Kennedy Institute) in collaboration with Prof Raashid Luqmani (Botnar Research Centre) and published in JCI Insight, identified an immature population of neutrophils that accumulates in the blood of GCA patients and attaches to the arterial vessel wall. The researchers found that reactive oxygen species (ROS) released by these neutrophils trigger changes in blood vessel cells, which could represent an early event in the development of inflammatory lesions.

GCA is one of a group of systemic vasculitides that causes inflammation in the large vessels in the head and neck. It is becoming increasingly common in an ageing population and can lead to significant health problems if untreated, including loss of sight.

To understand more about the cause of GCA, Irina's team analysed individual white blood cells in blood samples from GCA patients. They discovered that the main expansion in cell populations in active GCA was in neutrophils. Dr Lihui Wang, the first author on the paper says: "These cells are normally meant to fight microbes. But to do so they produce reactive oxygen species, among other mediators, which could be pathogenic in prolonged inflammatory conditions. Fully mature neutrophils quickly die, but immature neutrophils that in health are confounded to the bone marrow, live for much longer."

Irina continues, "We were excited to see this population of cells expanded in GCA, infiltrated blood vessels and produced large quantities of ROS. It damaged endothelial barrier and led to endothelial leakage. The same immature neutrophils have recently been linked to severe COVID-19, but the mechanisms are unknown. Thus, our discovery may shed light on the vascular pathology observed in COVID-19 as well."

The research was funded by Versus Arthritis and Oxford-Celgene fellowship programme and the Wellcome Trust.

Funded by

Versus Arthritis logo

Wellcome Trust

Similar stories

Yoshi Itoh wins the International Dupuytren Award 2022

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Taking a break from immune-suppressing medicines doubles the antibody response to COVID-19 booster vaccination

The Oxford Clinical Trials Research Unit (OCTRU) at NDORMS played a key role in the VROOM study which found that pausing immune-suppressing medicines such as methotrexate can increase the response to COVID-19 booster jabs.

Ten Years of Athena Swan in the Medical Sciences Division

2022 marks ten years since the first Athena Swan Bronze applications from the Medical Sciences Division. Ten years later, and all 16 departments in the Division have achieved a Silver Award. We look at NDORMS’ Athena Swan journey.

NDORMS researchers awarded Associate Professor title

The University of Oxford has awarded the title of Associate Professor to Adam Cribbs and Luke Jostins.

Oxford's largest ever study into varicose veins shows need for surgery is linked to genetics

A new international study by Oxford researchers published in Nature Communications, establishes for the first time a critical genetic risk score to predict the likelihood of patients suffering with varicose veins to require surgery, as well as pointing the way towards potential new therapies.

Reflecting on the role of Clinical Director of Trauma and Orthopaedics

In 2021 Professor Andrew Price was appointed Clinical Director of Trauma and Orthopaedics at the Oxford University Hospitals NHS Foundation Trust. After 9 months in post, we find out what the challenges are and what he’s been able to bring to the role.